Deleporte A, Van den Eynde M, Forget F, et al. - Researchers present the outcomes of a randomized phase II trial (DoGE study: Docetaxel in Gastric cancer treatment Evaluation study) assessing the safety as well as efficacy profile of two novel modified docetaxel/cisplatin/5-fluorouracil (DCF) regimens in the first-line setting of advanced gastric and gastroesophageal junction adenocarcinomas. Chemonaïve metastatic gastric adenocarcinoma patients were randomly assigned to fractionated weekly DCF (D 40 mg/m ² , C 35 mg/m ² , F 1800 mg/m ² over 24 h, on days 1 and 8 every 3 weeks, arm (1) or fortnightly DCF (D 50 mg/m ² , C 50 mg/m ² , F 2000 mg/m ² over 48 h every 2 weeks, arm (2). Overall 106 eligible patients were included in this study. Not only a low risk of early FN (the rate of febrile neutropenia within the first six treatment weeks) was observed in relation to fractionated weekly and fortnightly DCF regimens but also these regimens displayed a better hematological toxicity profile, without compromising efficacy, when compared with historical DCF. Both treatment regimens provided greater convenience eliminating the requirement for systematic use of prophylactic granulocyte colony-stimulating factor.